LACTOFERRINE FECALE EN TANT QUE BIOMARQUEUR POUR LA DETERMINATION DE LA SEVERITE D'UNE MALADIE ET POUR LA SURVEILLANCE D'UNE INFECTION CHEZ DES PATIENTS ATTEINTS PAR UNE MALADIE PAR CLOSTRIDIUM DIFFICILE
BOONE, JAMES HUNTER,LYERLY, DAVID M.,WILKINS, TRACY D.,CARMAN, ROBERT J.
申请号：
CA2834400
公开号：
CA2834400A1
申请日:
2012.04.27
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
